Lenz Therapeutics Stock Earnings Reports

LENZ Therapeutics reported Q1 2026 results consistent with prior expectations as it continues the early-stage commercial launch of VIZZ. Key operational highlights: ~25,000 paid & filled prescriptions in Q1 (46,000 total since launch), ~$1.9M net revenue ($1.7M product sales), and over 10,000 unique prescribers. Management sees encouraging real-world efficacy, early persistence (e.g., >2/3 of e-pharmacy volume now in 3‑month prescriptions), and stronger scripts-per-prescriber (roughly 30% higher vs. VUITY at a comparable launch stage). The company has identified adoption barriers — physicians not proactively raising VIZZ in routine exams and multi-step consumer funnel friction — and is executing targeted fixes (refined exam-room messaging, QR onboarding videos, enabling direct in-office sales where allowed, DTC optimization including select linear TV pilots, and expanded field force). Manufacturing is transitioning to an FDA-approved large-scale process to lower COGS and improve vial/formulation. Safety signals to date are favorable: after ~46,000 boxes (~1.2M doses) shipped, LENZ reports 0 retinal detachments and 2 retinal tears, both in patients with pre-existing retinal risk factors. Financials: Q1 net loss $41.5M (EPS -$1.32), SG&A $45M (≈80% sales & marketing), negligible R&D (expected to remain low), Q1 cash + equivalents ~$258.4M and net cash burn ~$34M. Management expects quarterly OPEX and cash burn to decline from the Q1 level and will begin reporting more detailed refill dynamics in H2 2026. Investors should monitor: NRx growth trajectory as new commercial initiatives scale (DTC, TV, field expansion), conversion/refill metrics (H2 disclosures), margin improvement as manufacturing transitions and COGS decline, and continued monitoring of safety/retina events as exposure increases.